They reported that VP3.15 (IC50 = 1.59 μM) reduced the clinical symptoms of EAE (at a dose of 10 mg/kg, intraperitoneally), similar to the action of fingolimod, a drug used in the treatment of multiple sclerosis, and was more effective than another PDE7 inhibitor, BRL-50481. The gene discussed is PDE7A; the disease is multiple sclerosis.